Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Cash from Financing Activities (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Cash from Financing Activities for 5 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • For Q3 2025, Cash from Financing Activities changed N/A year-over-year to $1.8 million; the TTM value through Sep 2025 reached $3.1 million, changed N/A, while the annual FY2023 figure was $5.0 million, 17224.14% up from the prior year.
  • Cash from Financing Activities hit $1.8 million in Q3 2025 for Cyclerion Therapeutics, up from -$130000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $30.6 million in Q2 2021 and bottomed at -$130000.0 in Q2 2025.
  • Average Cash from Financing Activities over 3 years is $3.8 million, with a median of $43000.0 recorded in 2021.
  • Year-over-year, Cash from Financing Activities soared 2600.0% in 2021 and then crashed 99.94% in 2022.
  • Cyclerion Therapeutics' Cash from Financing Activities stood at $85000.0 in 2021, then crashed by 85.88% to $12000.0 in 2022, then skyrocketed by 15116.67% to $1.8 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $1.8 million, -$130000.0, and $1.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.